Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Poolbeg Pharma moves closer to granting of patent for POLB 001 to treat multiple diseases
UK biopharmaceutical company Poolbeg Pharma (AIM: POLB) has received a notice of allowance from the US Patent Office in relation to an application for its lead candidate POLB 001 in the treatment of multiple diseases. The notice covers a class of drugs (including POLB 001) for treating hypercytokinaemia (cytokine storm) and for preventing its development […]
March 21, 2024
Latest Stories
Faron Pharma reports improved remission rates from Bexmab Phase 1 trial to treat patients with aggressive cancers
Faron Pharmaceuticals (LSE: FARN) has reported positive data from Phase 1 of an ongoing trial investigating bexmarilimab (Bexmab) in combination with standard of care in aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Four out of five initial Phase 1 patients have now been on Bexmab with azacitidine for more than […]
Ondine Biomedical’s Steriwave antimicrobial to be rolled out in eight new healthcare facilities
Ondine Biomedical (LSE: OBI) has announced that its Steriwave nasal photodisinfection and chlorhexidine skin decolonisation technology will be deployed in eight new healthcare facilities worldwide, including six hospitals. The commercial deals are paid adoptions which had begun or were agreed to before the end of February. The first three are at hospitals in Spain and […]
AstraZeneca spends US$1.05b to acquire Amolyt Pharma and boost its rare disease portfolio
Global pharmaceutical company AstraZeneca (LSE: AZN) will part with US$1.05 billion to buy-out French biotech Amolyt Pharma, which is focused on the development of novel treatments for rare endocrine diseases. Under the terms of the transaction, AstraZeneca will acquire all of Amolyt’s outstanding shares on a cash and debt-free basis. It will include an US$800 […]
